Delivery of Factor VIII Gene into Skeletal Muscle Cells Using Lentiviral Vector
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study was designed to investigate whether transduction of lentiviral vectors (LV) carrying human coagulation factor VIII (hFVIII) cDNA into skeletal muscle could increase circulating hFVIII concentrations. Materials and Methods: A LV containing bacterial LacZ gene as a control or human FVIII gene was intramuscularly administered into the thigh muscle of 5 weeks old Sparague-Dawley rats. The plasma human FVIII concentration and neutralizing anti-FVIII antibodies were measured for up to 12 weeks in these experimental animals. Results: The plasma human FVIII levels in the rats injected with LV carrying FVIII cDNA peaked at post-injection 1st week (5.19 ± 0.14 ng/mL vs. 0.21 ± 0.05 ng/mL in control rats , p < 0.05). Elevated hFVIII concentrations were maintained for 4 weeks (2.52 ± 0.83 ng/mL vs. 0.17 ± 0.08 ng/mL in control rats, p < 0.05)after a single intramuscular injection. In the Bethesda assay, neutralizing antibodies for FVIII protein were detected only in FVIII-LV injected rats by the 10th week, but not in control rats. Conclusion: This study suggested that a single administration of an advanced generation LV carrying the human FVIII cDNA resulted in elevation of FVIII level in immune competent rats, and that this gene transfer approach to the skeletal muscle could be an effective tool in treatment of hemophilia A.
Abstract
Purpose: This study was designed to investigate whether transduction of lentiviral vectors (LV) carrying human coagulation factor VIII (hFVIII) cDNA into skeletal muscle could increase circulating hFVIII concentrations. Materials and Methods: A LV containing bacterial LacZ gene as a control or human FVIII gene was intramuscularly administered into the thigh muscle of 5 weeks old Sparague-Dawley rats. The plasma human FVIII concentration and neutralizing anti-FVIII antibodies were measured for up to 12 weeks in these experimental animals. Results: The plasma human FVIII levels in the rats injected with LV carrying FVIII cDNA peaked at post-injection 1st week (5.19 ± 0.14 ng/mL vs. 0.21 ± 0.05 ng/mL in control rats , p < 0.05). Elevated hFVIII concentrations were maintained for 4 weeks (2.52 ± 0.83 ng/mL vs. 0.17 ± 0.08 ng/mL in control rats, p < 0.05)after a single intramuscular injection. In the Bethesda assay, neutralizing antibodies for FVIII protein were detected only in FVIII-LV injected rats by the 10th week, but not in control rats. Conclusion: This study suggested that a single administration of an advanced generation LV carrying the human FVIII cDNA resulted in elevation of FVIII level in immune competent rats, and that this gene transfer approach to the skeletal muscle could be an effective tool in treatment of hemophilia A.
참고문헌 (25)
- Kaufman RJ, "Advances toward gene therapy for hemophilia at the millennium", Hum Gene Ther, 10, pp.2091~2107 (1999)
- Levine P, "Clinical manifestations an therapy of hemophilia A and B. In Hemostasis and Thrombosis. 2nd ed.", pp.97~111 (1987), JB Lippincott
- Furie B, "A practical guide to the evaluation and treatment of hemophilia", Blood, 84, pp.3~9 (1994)
- Saenko EL, "The future of recombinant coagulation factors", J Thromb Haemost, 1, pp.922~930 (2003)
- Kreuz W, "Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products", Semin Thromb Hemost, 28, pp.285~290 (2002)
- Wion KL, "Distribution of factor VIII mRNA and antigen in human liver and other tissues", Nature, 317, pp.726~729 (1985)
- Hollestelle MJ, "Tissue distribution of factor VIII gene expression in vivo--a closer look", Thromb Haemost, 86, pp.855~861 (2001)
- Zelechowska MG, "Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes", Nature, 317, pp.729~730 (1985)
- VandenDriessche T, "Viral vector-mediated gene therapy for hemophilia", Curr Gene Ther, 1, pp.301~315 (2001)
- Zufferey R, "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo", Nat Biotechnol, 15, pp.871~875 (1997)
- Park F, "Efficient lentiviral transduction of liver requires cell cycling in vivo", Nat Genet, 24, pp.49~52 (2000)
- Park F, "Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver", Blood, 96, pp.1173~1176 (2000)
- Do H, "Expression of factor VIII by murine liver sinusoidal endothelial cells", J Biol Chem, 274, pp.19587~19592 (1999)
- Dull T, "A third generation lentivirus vector with a conditional packaging system", J Virol, 72, pp.8463~8471 (1998)
- Oh TK, "Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene", Am J Nephrol, 26, pp.326~334 (2006)
- Pittman DD, "Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII", Blood, 81, pp.2925~2935 (1993)
- Bihoreau N, "Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain", Biochem J, 277, pp.23~31 (1991)
- Toole JJ, "A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity", Proc Natl Acad Sci U S A, 83, pp.5939~5942 (1986)
- Ogata K, "Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agm TYO1-based vector for hemophilia A gene therapy", Gene Ther, 11, pp.253~259 (2004)
- Ishiwata A, "Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene", Thromb Res, 118, pp.627~635 (2006)
- Dull T, "A third-generation lentivirus vector with a conditional packaging system", J Virol, 72, pp.8463~8471 (1998)
- Moayeri M, "Correction of murine hemophilia A by hematopoietic stem cell gene therapy", Mol Ther, 12, pp.1034~1042 (2005)
- Kang Y, "Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer", Blood, 106, pp.1552~1558 (2005)
- Shi Q, "Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies", J Clin Invest, 116, pp.1974~1982 (2006)
- Liu L, "Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon", Mol Ther, 13, pp.1006~1015 (2006)